Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2022 Jan 27
Why We Did What We Did: PSMA PET/CT Selection Criteria for the VISION Trial.
Related Questions
If the majority of lesions are PSMA positive lesions, do you proceed with Lutetium, and if so, how do you treat or consider therapy to the PSMA negati...
New answer by Radiation Oncologist at Corewell Health (April 28, 2025)
The tl;dr answer: If the patient met VISION criteria for exclusion based on PSMA-negative disease burden, then yes, I would most likely not recommend Pluvicto and would p...